Skip to main content
Erschienen in: Arthritis Research & Therapy 1/2017

Open Access 01.12.2017 | Research article

Acupuncture decreased the risk of coronary heart disease in patients with fibromyalgia in Taiwan: a nationwide matched cohort study

verfasst von: Mei-Yao Wu, Ming-Cheng Huang, Jen-Huai Chiang, Mao-Feng Sun, Yu-Chen Lee, Hung-Rong Yen

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2017

Abstract

Background

The aim of this study was to understand whether acupuncture can decrease the risk of coronary heart disease (CHD) in patients with fibromyalgia.

Methods

Using data from the Taiwanese National Health Insurance Research Database, we performed a propensity score-matched cohort study to analyze patients with fibromyalgia diagnosed between 1 January 2000 and 31 December 2010. Patients who received acupuncture treatment, beginning with their initial date of fibromyalgia diagnosis and extending to 31 December 2010, were regarded as the acupuncture cohort. The no-acupuncture cohort comprised patients who never received acupuncture through 31 December 2010. A Cox regression model was used to adjust for age, sex, comorbidities, and drugs used. The HRs of the acupuncture and no-acupuncture cohorts were compared.

Results

After performing a 1:1 propensity score match, 58,899 patients in both cohorts were identified. Baseline characteristics were similar in both cohorts. The cumulative incidence of CHD was significantly lower in the acupuncture cohort (log-rank test, p < 0.001). In the follow-up period, 4389 patients in the acupuncture cohort (17.44 per 1000 person-years) and 8133 patients in the no-acupuncture cohort (38.36 per 1000 person-years) developed CHD (adjusted HR 0.43, 95% CI 0.41–0.45). The beneficial effect of acupuncture on the incidence of CHD was independent of age, sex, comorbidities, and statins used.

Conclusions

Our study confirmed that acupuncture reduced the risk of CHD in patients with fibromyalgia in Taiwan. Further clinical and mechanistic studies are warranted.
Abkürzungen
BMI
Body mass index
CHD
Coronary heart disease
DM
Diabetes mellitus
FDA
U.S. Food and Drug Administration
HSP
Heat shock protein
ICD-9-CM
International Classification of Diseases, Ninth Revision, Clinical Modification
IR
Incidence rate
LHID 2000
Longitudinal Health Insurance Database 2000
NHI
National Health Insurance
NHIA
National Health Insurance Administration
NHIRD
National Health Insurance Research Database
NMDAR
N-methyl-d-aspartate receptor
NSAID
Nonsteroidal anti-inflammatory drug
QOL
Quality of life
TCM
Traditional Chinese medicine
TRPV1
Transient receptor potential vanilloid 1

Background

Fibromyalgia, characterized by chronic widespread pain, commonly presents with associated symptoms such as fatigue, sleep disturbance, depression, cognitive dysfunction, and headache [1, 2]. The American College of Rheumatology published the criteria for fibromyalgia, which were modified in 2010 [3]. The global mean prevalence of fibromyalgia in the general population was 2.7%, and the female-to-male ratio was 3:1 [4]. The quality of life (QOL) of patients with fibromyalgia is always impaired, and about one-third of patients have difficulties in performing the activities of daily living. The high incidence of comorbidities is another health care problem. Researchers in previous studies reported that patients with fibromyalgia in the United States were two to seven times more likely to have comorbidities [5]. According to the U.S. National Health Interview Survey, myocardial infarction occurred more than twice as often in patients with fibromyalgia as in patients without fibromyalgia [6]. In Korea, chronic emotional stress in postmenopausal women with fibromyalgia impaired myocardial function [7]. In Taiwan, a population-based cohort study revealed that the risk of coronary heart disease (CHD) in patients with fibromyalgia was 47% higher than in the general population [8].
Current treatment strategies for fibromyalgia include pharmacological and nonpharmacological methods. Pregabalin, duloxetine, and milnacipran are U.S. Food and Drug Administration (FDA)-approved drugs for treating patients with fibromyalgia, but the efficacy of these drugs has been questioned because of the small sample sizes in clinical trials [9]. Nonpharmacological treatments of fibromyalgia include acupuncture, massage, and exercise. Because the pathological mechanisms of fibromyalgia are not yet fully understood, current treatments are focused on attenuating symptoms and improving QOL.
Animal studies and clinical trials revealed that acupuncture has a beneficial effect in the treatment of fibromyalgia [10, 11]. However, there is no long-term follow-up study showing whether acupuncture can decrease the risk of CHD in patients with fibromyalgia. The Taiwanese National Health Insurance Research Database (NHIRD) provides information on the entire population of Taiwan with long-term follow-up data for interventions. The advantage of using this database is that it prevents sampling bias [12]. The National Health Insurance (NHI) program was implemented in 1995 in Taiwan by the National Health Insurance Administration (NHIA). Traditional Chinese medicine (TCM) services have been reimbursed through the NHI program since 1996 [13]. The use of TCM services, including herbal medicine and acupuncture, is common in Taiwan for the treatment of many kinds of disease [1417]. To understand whether acupuncture can decrease the risk of CHD in patients with fibromyalgia, we investigated a randomly selected sample of 1 million people enrolled in the NHIRD from 2000 to 2010.

Methods

Data sources

We conducted a nationwide, population-based, 1:1 propensity score-matched cohort study by analyzing data derived from the NHIRD. The data source of our study was the Longitudinal Health Insurance Database 2000, which contains all the original claims data of 1 million beneficiaries randomly sampled from the registry of all beneficiaries in 2000. The sampled patients exhibited no significant difference in age, sex, birth year, or average insured payroll-related costs from the general population. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes were used for diagnoses. Because the NHIRD contains identified secondary data for research, the present study was waived from the need for informed consent. This study was approved by the research ethics committee of China Medical University and Hospital (CMUH104-REC2-115).

Study cohort identification

Patients newly diagnosed with fibromyalgia from 1 January 2000 to 31 December 2010 were identified (Fig. 1). To be included, patients with fibromyalgia should have had at least two ambulatory or inpatient claims with the diagnosis of ICD-9-CM codes 729.0 and 729.1. The exclusion criteria included age younger than 18 years, incomplete information on age and sex, and withdrawal from the NHIRD during the follow-up period. Patients who received acupuncture from their initial diagnosis of fibromyalgia to 31 December 2010 were identified as the acupuncture cohort. Propensity score approaches were used to reduce confounding by the indication of acupuncture treatment. We used a 1:1 propensity score match by sex, age (per 5 years), comorbidities, drugs used, and the year in which fibromyalgia was diagnosed through multiple logistic regression analysis. Ultimately, equal numbers of patients in the acupuncture and no-acupuncture cohorts were analyzed in this study. The immortal time of acupuncture cohort was the period between the first time of receiving acupuncture and the date of initial diagnosis with fibromyalgia. The claims data for both cohorts were assessed from the initial diagnosis date to 31 December 2011 (the end of this study).

Covariate assessment

Sociodemographic factors included age and sex. Patients were divided into three groups according to their age (18–39 years, 40–59 years, and older than 60 years). Baseline comorbidities were considered present if ICD-9-CM codes appeared two or more times in outpatient or inpatient claims before the initial diagnosis of fibromyalgia, which included diabetes mellitus (DM; ICD-9-CM code 250), hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code 272), congestive heart failure (ICD-9-CM codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.0), stroke (ICD-9-CM codes 430–438), depression (ICD-9-CM codes 296.2–296.3, 300.4, and 311), anxiety (ICD-9-CM codes 300.0, 300.2, 300.3, 308.3, and 308.91), alcoholism or alcohol-related disorders (ICD-9-CM codes 291, 303, 305.00–305.03, 790.3, and V11.3), tobacco dependence (ICD-9-CM code 305.1), and obesity (ICD-9-CM codes 278 and A183).

Types of acupuncture and disease categories in the acupuncture cohort

We analyzed the acupuncture type that patients received by the treatment codes, which included manual acupuncture of TCM type (B41, B42, B45, B46, B80-B84, B90–B94, P27041, P31103, P32103, and P33031) and electroacupuncture (B43, B44, B86–B89, and P33032). Disease categories for which patients with fibromyalgia received acupuncture were identified by the ICD-9-CM codes. More than one ICD-9-CM code may be recorded when patients receive acupuncture, so the total numbers of patients in all categories were more than the number of patients in the acupuncture cohort.

Statistical analyses

We compared the baseline characteristics of the acupuncture and no-acupuncture cohorts using standardized mean differences. Standardized mean differences with less than 0.1 SD indicated a negligible difference in mean values or proportions between the two cohorts. The HR and 95% CI were calculated for each variable by Cox proportional hazards regression. The difference between the two cohorts in the development of CHD was estimated using the Kaplan-Meier method and the log-rank test.
Statistical analysis was performed and figures were created using SAS 9.4 (SAS Institute, Cary, NC, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria). p < 0.05 in two-tailed tests indicated statistical significance.

Results

Using the NHIRD, we identified 189,512 patients with fibromyalgia newly diagnosed between 1 January 2000 and 31 December 2010 (Fig. 1). After excluding patients with missing information or lacking follow-up, 158,425 patients were included. Among included patients, 81,843 received acupuncture and 76,582 patients never received acupuncture from the initial fibromyalgia diagnosis date to 31 December 2010. To minimize the differences in basic data between these two cohorts, we used a 1:1 propensity score match to randomly select 58,899 patients each for the acupuncture and no-acupuncture cohorts.
The baseline characteristics of both cohorts are shown in Table 1, and they were similar in sex, age, comorbidities, and drugs used. The proportion of women was higher than men in both cohorts, and the dominant age group was 40–59 years. The most common comorbidity was hypertension, which was present in more than 20% of patients. Among the patients with fibromyalgia, 17% had hyperlipidemia, 11% had anxiety, 10.6% had DM, 6.9% had stroke, 4.9% had depression, and 1% had congestive heart failure. The proportions of patients diagnosed with alcoholism or alcohol-related disorders, tobacco dependence, and obesity were similar in both cohorts. Almost all patients in both cohorts used nonsteroidal anti-inflammatory drugs (NSAIDs), and approximately 67% of patients used oral steroids. About 13.5% of patients took statins for hyperlipidemia in the no-acupuncture and acupuncture cohorts. The mean duration between the initial diagnosis of fibromyalgia and the first time receiving acupuncture was approximately 919 days. The average number of acupuncture visits was 7.45. Most patients (85%) received manual acupuncture of TCM type, and 3.6% patients received electroacupuncture. About 10.7% of patients received both types of treatment.
Table 1
Characteristics of patients with fibromyalgia in the present study
Variable
No acupuncture (n = 58,899)
Acupuncture (n = 58,899)
Standardized mean difference
n
%
n
%
Sex
 Female
33,331
56.59
33,447
56.79
0.004
 Male
25,568
43.41
25,452
43.21
 
Age group, years
 18–39
24,487
41.57
23,572
40.02
0.032
 40–59
27,481
46.66
29,748
50.51
0.077
 ≥60
6931
11.77
5579
9.47
0.075
 Mean (±SD), years
44.57 (15.43)
44.28 (14.44)
0.02
Baseline comorbidities
 Diabetes mellitus
6252
10.61
6098
10.35
0.009
 Hypertension
12,457
21.15
12,036
20.43
0.018
 Hyperlipidemia
10,097
17.14
10,034
17.04
0.003
 Congestive heart failure
569
0.97
508
0.86
0.011
 Cerebrovascular diseases
4044
6.87
3786
6.43
0.018
 Depression
2863
4.86
2840
4.82
0.002
 Anxiety
6551
11.12
6600
11.21
0.003
 Alcoholism or alcohol-related disorders
311
0.53
316
0.54
0.001
 Tobacco dependence
289
0.49
270
0.46
0.005
 Obesity
439
0.75
427
0.72
0.002
Drugs used
 Oral steroids
39466
67.01
39495
67.06
0.001
 NSAIDs
57613
97.82
57734
98.02
0.014
 Statins
7971
13.53
7937
13.48
0.002
Types of acupuncture
 Manual acupuncture of TCM type
50,470
85.69
 
 Electroacupuncture
2142
3.64
 
 Combination of manual acupuncture and electroacupuncture
  
6287
10.67
 
Duration between the initial diagnosis to the first acupuncture treatment, days, mean (median)
919 (574)
 
Acupuncture visits, mean
7.45
 
Follow-up duration, years, mean (median)
3.60 (3.02)
4.27 (3.79)
 
NSAIDs Nonsteroidal anti-inflammatory drugs, TCM Traditional Chinese medicine
During the follow-up period, there were 12,522 patients included in our study who developed CHD (Table 2). The incidence of CHD in patients with fibromyalgia increased depending on age (adjusted HRs 4.24 and 6.24 in 40–59 years and ≥60 years age groups, respectively). Patients with fibromyalgia with comorbidities also developed CHD more easily than patients without comorbidities. Overall, the incidence of CHD was significantly lower in the acupuncture cohort than in the no-acupuncture cohort (adjusted HR 0.43, 95% CI 0.41–0.45).
Table 2
Hazard ratios of coronary heart disease associated with acupuncture and covariates among patients with fibromyalgia
Variable
Number of events (n = 12,522)
Crude HR
(95% CI)
p Value
Adjusted HR
(95% CI)
p Value
Received acupuncture
 No
8133
1.00
Reference
 
1.00
Reference
 
 Yes
4389
0.48
(0.46–0.5)
<0.0001
0.43
(0.41–0.45)
<0.0001
Sex
 Female
7138
1.00
Reference
 
1.00
Reference
 
 Male
5384
0.98
(0.95–1.02)
0.3907
1.03
(0.99–1.07)
0.1072
Age group, years
 18–39
1248
1.00
Reference
 
1.00
Reference
 
 40–59
7946
5.24
(4.94–5.56)
<0.0001
4.24
(3.99–4.51)
<0.0001
 ≥60
3328
11.33
(10.62–12.1)
<0.0001
6.24
(5.81–6.71)
<0.0001
Baseline comorbidities (reference = nonsite comorbidity)
 Diabetes mellitus
2994
2.9
(2.78–3.02)
<0.0001
1.37
(1.31–1.44)
<0.0001
 Hypertension
6188
4.03
(3.89–4.18)
<0.0001
2.20
(2.11–2.3)
<0.0001
 Hyperlipidemia
4452
2.88
(2.78–2.99)
<0.0001
1.63
(1.56–1.7)
<0.0001
 Congestive heart failure
298
3.19
(2.85–3.58)
<0.0001
1.17
(1.04–1.32)
0.0078
 Cerebrovascular diseases
1966
2.81
(2.68–2.95)
<0.0001
1.25
(1.19–1.32)
<0.0001
 Depression
803
1.48
(1.38–1.59)
<0.0001
1.1
(1.02–1.18)
0.0131
 Anxiety
1960
1.61
(1.53–1.69)
<0.0001
1.21
(1.15–1.27)
<0.0001
 Alcoholism or alcohol-related disorders
57
0.97
(0.75–1.25)
0.8031
0.93
(0.72–1.21)
0.5941
 Tobacco dependence
39
0.9
(0.66–1.23)
0.5098
0.83
(0.6–1.13)
0.2391
 Obesity
109
1.34
(1.11–1.62)
0.0024
1
(0.83–1.21)
0.9629
Drugs used
 Oral steroids
7490
0.62
(0.6–0.64)
<0.0001
0.54
(0.52–0.56)
<0.0001
 NSAIDs
11,804
0.21
(0.19–0.23)
<0.0001
0.24
(0.22–0.26)
<0.0001
 Statins
2218
1.28
(1.22–1.34)
<0.0001
0.55
(0.52–0.58)
<0.0001
NSAIDs Nonsteroidal anti-inflammatory drugs
a Crude HR represents relative hazard ratio
b Adjusted HR represents adjusted hazard ratio mutually adjusted for accepted acupuncture, age, sex, diabetes mellitus, hypertension, hyperlipidemia, congestive heart failure, cerebrovascular diseases, depression, anxiety, alcoholism or alcohol-related disorders, tobacco dependence, obesity, oral steroids, NSAIDs, and statins in Cox proportional hazards regression
Figure 2 reveals that the cumulative incidence of CHD was significantly lower in the acupuncture cohort during the follow-up period (log-rank test, p < 0.001). In this study, 4389 patients in the acupuncture cohort (17.44 per 1000 person-years) and 8133 patients in the no-acupuncture cohort (38.36 per 1000 person-years) developed CHD (adjusted HR 0.43, 95% CI 0.41–0.45) (Table 3). The beneficial effect of acupuncture on the incidence of CHD was observed in both female and male patients (adjusted HR 0.48 in women, 95% CI 0.46–0.51; adjusted HR 0.47 in men, 95% CI 0.45–0.50). Although the risk of CHD gradually increased with age, acupuncture significantly decreased the incidence of CHD in all age groups. Acupuncture decreased the risk of CHD in patients with fibromyalgia with or without comorbidities. Regardless of whether patients took oral steroids, NSAIDs, or statins, fewer patients in the acupuncture cohort developed CHD than in the no-acupuncture cohort.
Table 3
Incidence rates and hazard ratios for coronary heart disease among patients with fibromyalgia with or without acupuncture treatment
Variable
No acupuncture (n = 58,899)
Acupuncture (n = 58,899)
  
Events
Person-years
IR
Events
Person-years
IR
Crude HR (95% CI)
Adjusted HRa (95% CI)
Total
8133
212,027
38.36
4389
251,711
17.44
0.48 (0.46–0.50)b
0.43 (0.41–0.45)b
Sex
 Female
4650
120,934
38.45
2488
141,235
17.62
0.48 (0.46–0.51)b
0.43 (0.41–0.45)b
 Male
3483
91,093
38.24
1901
110,476
17.21
0.47 (0.45–0.5)b
0.45 (0.43–0.48)b
Age group, years
 18–39
877
92,941
9.44
371
94,477
3.93
0.42 (0.38–0.48)b
0.39 (0.35–0.44)b
 40–59
5059
99,271
50.96
2887
133,190
21.68
0.45 (0.43–0.47)b
0.42 (0.41–0.44)b
 ≥60
2197
19,814
110.88
1131
24,044
47.04
0.48 (0.45–0.52)b
0.47 (0.43–0.5)b
Baseline comorbidities
 Diabetes mellitus
  No
6227
193,111
32.25
3301
225,893
14.61
0.47 (0.45–0.5)b
0.44 (0.42–0.46)b
  Yes
1906
18,916
100.76
1088
25,818
42.14
0.46 (0.42–0.49)b
0.44 (0.41–0.47)b
 Hypertension
  No
4148
174,292
23.80
2186
199,801
10.94
0.48 (0.45–0.5)b
0.43 (0.41–0.46)b
  Yes
3985
37,735
105.61
2203
51,910
42.44
0.44 (0.42–0.47)b
0.44 (0.42–0.46)b
 Hyperlipidemia
  No
5328
180,288
29.55
2742
210,271
13.04
0.46 (0.44–0.48)b
0.43 (0.41–0.45)b
  Yes
2805
31,738
88.38
1647
41,440
39.74
0.49 (0.46–0.52)b
0.46 (0.43–0.49)b
 Congestive heart failure
  No
7942
210,670
37.70
4282
249,749
17.15
0.48 (0.46–0.5)b
0.44 (0.42–0.45)b
  Yes
191
1356
140.83
107
1963
54.52
0.45 (0.35–0.57)b
0.46 (0.36–0.59)b
 Cerebrovascular diseases
  No
6867
199,807
34.37
3689
235,364
15.67
0.48 (0.46–0.5)b
0.44 (0.42–0.45)b
  Yes
1266
12,220
103.60
700
16,348
42.82
0.46 (0.42–0.5)b
0.45 (0.41–0.49)b
 Depression
  No
7628
203,237
37.53
4091
240,799
16.99
0.48 (0.46–0.49)b
0.44 (0.42–0.45)b
  Yes
505
8790
57.45
298
10,912
27.31
0.51 (0.44–0.59)b
0.46 (0.4–0.53)b
 Anxiety
  No
6860
191,626
35.80
3702
225,730
16.40
0.48 (0.46–0.5)b
0.44 (0.42–0.46)b
 Yes
1273
20,401
62.40
687
25,982
26.44
0.46 (0.42–0.5)b
0.43 (0.39–0.47)b
 Alcoholism or alcohol-related disorders
  No
8093
211,137
38.33
4372
250,521
17.45
0.48 (0.46–0.5)b
0.44 (0.42–0.46)b
  Yes
40
889
44.99
17
1190
14.28
0.35 (0.2–0.61)b
0.33 (0.19–0.6)b
 Tobacco dependence
  No
8109
211,341
38.37
4374
251,047
17.42
0.48 (0.46–0.5)b
0.44 (0.42–0.45)b
  Yes
24
685
35.02
15
664
22.58
0.68 (0.35–1.29)
0.47 (0.23–0.94)c
 Obesity
 No
8062
210,777
38.25
4351
250,115
17.40
0.48 (0.46–0.5)b
0.44 (0.42–0.46)b
 Yes
71
1250
56.80
38
1596
23.81
0.45 (0.3–0.66)b
0.36 (0.24–0.55)b
Drugs used
 Oral steroids
  No
3458
56,042
61.70
1574
74,258
21.20
0.39 (0.37–0.41)b
0.39 (0.37–0.42)b
  Yes
4675
155,985
29.97
2815
177,453
15.86
0.54 (0.52–0.57)b
0.49 (0.46–0.51)b
 NSAIDs
  No
543
1878
289.11
175
3206
54.58
0.27 (0.23–0.32)b
0.31 (0.26–0.37)b
  Yes
7590
210,148
36.12
4214
248,505
16.96
0.49 (0.47–0.51)b
0.45 (0.44–0.47)b
 Statins
  No
6799
179,722
37.83
3505
215,745
16.25
0.46 (0.44–0.48)b
0.42 (0.4–0.44)b
  Yes
1334
32,305
41.29
884
35,967
24.58
0.6 (0.55–0.66)b
0.56 (0.52–0.61)b
IR Incidence rate per 1000 person-years; NSAIDs Nonsteroidal anti-inflammatory drugs
a Adjusted HR adjusted for accepted acupuncture, age, sex, diabetes mellitus, hypertension, hyperlipidemia, congestive heart failure, cerebral vascular diseases, depression, anxiety, alcoholism or alcohol-related disorders, tobacco dependence, obesity, oral steroids, NSAIDs, and statins in Cox proportional hazards regression
b p < 0.001
c p < 0.05
Table 4 reveals the top ten disease categories for which the patients with fibromyalgia in the acupuncture cohort received acupuncture treatment. The most common conditions leading to visiting acupuncture doctors were disorders of the musculoskeletal system and connective tissues that are highly related to fibromyalgia. Injury was also a common reason for receiving acupuncture.
Table 4
Top ten disease categories as reasons for clinical acupuncture visits in the acupuncture cohort
Disease categories (ICD-9-CM codes)
Acupuncture cohort (n = 58,899)
Disorders of musculoskeletal system and connective tissue (710–739)
42,488
Injury and poisoning (800–999)
36,465
Symptoms, signs, and ill-defined conditions (780–799)
4014
Disorders of nervous system (320–389)
2802
Disorders of digestive system (520–579)
1714
Disorders of respiratory system (460–519)
1497
Disorders of circulatory system (390–459)
850
Disorders of genitourinary system (580–629)
725
Disorders of skin and subcutaneous tissue (680–709)
335
Mental disorders (290–319)
283
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification
More than one ICD-9-CM code can be recorded when patients receive acupuncture

Discussion

To our knowledge, our present nationwide population-based study is the first to reveal that acupuncture decreases the risk of CHD in patients with fibromyalgia. As a popular treatment for fibromyalgia, acupuncture has been performed on patients with fibromyalgia in several clinical trials. However, the outcome evaluation was previously always focused on pain score, sleep quality, and QOL [10]. In our study, we found that the beneficial effects of acupuncture on developing CHD in patients with fibromyalgia were independent of sex, age, comorbidities, and anti-inflammatory drugs included in our data. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase for treating hyperlipidemia, were previously reported to reduce the risk of cardiovascular diseases [18]. Our study revealed that regardless of whether patients with fibromyalgia took statins, acupuncture lowered the risk of CHD.
Our study revealed that more than half of patients with fibromyalgia in Taiwan have received acupuncture. A previous report revealed that the leading reason for patients in Taiwan to seek acupuncture treatment was diseases of the musculoskeletal system and connective tissue [19]. Fibromyalgia also belongs to this disease category. This is true not only in Taiwan, because patients with fibromyalgia also receive acupuncture in the other countries, such as Germany [20]. Previous studies in the United States, Spain, and Iran have demonstrated the efficacy of acupuncture in fibromyalgia [2123].
A strength of our study is the comprehensive, large-scale database that we used, Taiwan’s NHIRD. This database provides an enormous sample size to reduce selection and participation bias, and it includes long-term follow-up data [12]. In addition, the characteristics of patients with fibromyalgia in our study were consistent with those in previous reports of female and middle-aged predominance in other countries [6, 24]. These baseline characteristics were similar in both cohorts in our study.
In Taiwan, the majority of TCM doctors are graduated from baccalaureate TCM education programs (7- or 8-year medical doctor programs) or postbaccalaureate TCM programs (5-year medical doctor programs) in universities. The graduated students must pass the board examination conducted by the government. The training programs on the manipulation of acupuncture are standardized. The duration of needle retention most commonly performed is about 20–30 minutes in Taiwan, and achievement of deqi is a basic requirement in acupuncture treatment.
Pregabalin was the first FDA-approved drug for treatment of fibromyalgia [1]. It was demonstrated to improve pain, sleep disturbance, and fatigue in adult patients with fibromyalgia [25]. In our present study, we did not compare the efficacy of acupuncture with pregabalin, because this drug was not reimbursed by Taiwanese NHIA for fibromyalgia until 2015. Whether pregabalin decreases the incidence of CHD in patients with fibromyalgia has never been reported. Furthermore, pregabalin has cardiac adverse effects because it may induce heart failure [26]. Acupuncture has been reported to attenuate both ischemic injury of the heart and heart failure [27, 28]. Whether acupuncture treatment provides benefits to those patients receiving pregabalin deserves future investigation.
Fibromyalgia is thought to arise from aberrant brain chemistry, function, and structure [29]. The effects of acupuncture have also been documented to affect the central nervous system to ameliorate fibromyalgia [30]. An increasing body of evidence suggests that central sensitization contributes to hyperalgesia and allodynia in patients with fibromyalgia. Activation of N-methyl-d-aspartate receptor (NMDAR) and cyclic adenosine monophosphate-responsive element binding protein promotes hyperalgesia [29]. In a previous study on fibromyalgia, researchers using a murine model found that activation of the dorsal root ganglion was suppressed by acupuncture [31]. Activation of cardiac NMDAR induces oxidative stress and facilitates atrial fibrillation that were attenuated by NMDAR antagonists [32, 33]. Inhibition of NMDAR is the possible mechanism to prevent CHD in fibromyalgia, and whether acupuncture can suppress cardiac NMDAR in fibromyalgia needs further evaluation.
Other than the NMDAR pathway, the 5-HT3 receptor may be another target of acupuncture to decrease CHD in fibromyalgia. The analgesic effect of acupuncture is also evident through the 5HT3 receptor in a rat model of collagenase-induced arthritis, and 5-HT3 receptor antagonists have beneficial effects on autonomic cardiac dysfunction in patients with fibromyalgia [34, 35]. However, the results of our present study were contrary to those of a previous study involving transient receptor potential vanilloid 1 (TRPV1). Overexpression of TRPV1 in the spinal cord was suppressed by acupuncture in a fibromyalgia murine model [11], but TRPV1 in the endothelium prevents CHD [36]. The heart-protective effect of acupuncture in fibromyalgia may not be through the TRPV1 pathway.
Antidepression, anti-inflammation, and improvement of sleep quality are also possible mechanisms of acupuncture to prevent CHD in fibromyalgia. In previous reports, acupuncture improved sleep quality in patients with insomnia, which is highly associated with fibromyalgia and CHD [3739]. Depression is a common associated symptom of fibromyalgia, and it increases the incidence of CHD through deregulation of the autonomic nervous system and the hypothalamic-pituitary-adrenal axis [40]. Acupuncture stabilized this axis, activated the hippocampal serotonin system, and suppressed inflammation to attenuate depression [41, 42].
Comorbidities of fibromyalgia, including DM, hypertension, and heart disease, are highly associated with chronic inflammation. Many previous studies of acupuncture were focused on the analgesic effect of acupuncture, but additional studies in recent years demonstrated that acupuncture attenuated inflammation. Acupuncture attenuated inflammation through the vagus nerve mediated by dopamine [43]. The combination of acupuncture and moxibustion relieved Crohn’s disease by decreasing the ratio of Th17 to Treg cells in the intestinal mucosa [44]. These studies support that acupuncture has not only an analgesic effect but also an anti-inflammatory effect.
In addition, researchers in a previous study found that acupuncture before percutaneous coronary intervention in patients with acute myocardial infarction attenuated cardiac injury [45]. Acupuncture also decreased myocardial infarct areas and preserved cardiac function through heat shock protein 20 (HSP20) and HSP27 in an animal study [27]. These reports demonstrated that acupuncture can protect the heart from ischemia. Future mechanistic study in this area is warranted.
Several limitations in our study are noted. First, the NHIRD did not provide the severity of fibromyalgia, including pain scores, the severity of inflammation, or daily life disabilities. To minimize the confounding factors, we performed a 1:1 propensity score match and found that the baseline characteristics of both cohorts were similar. The percentages of patients who used NSAIDs and oral steroids were also similar in both cohorts. The second limitation is that the NHIRD did not provide data about patients’ lifestyles, such as smoking, alcohol drinking, body mass index (BMI), stress, and exercise. Although detailed information about smoking exposure, alcohol drinking, and BMI was not available, we were able to acquire information on illnesses resulting from these personal habits and lifestyles. We conducted a 1:1 propensity score match that included the diagnoses of alcoholism or alcohol-related disorders, tobacco dependence, and obesity. Patients with these disorders were similar in both cohorts, and the protective effect of acupuncture on CHD was significant in patients with fibromyalgia with these comorbid diseases. However, there was still an underestimation of smoking exposure and alcohol drinking in both cohorts. On the basis of our findings in this matched cohort study, we have designed a prospective participant- and assessor-blinded, randomized controlled trial to investigate the efficacy and mechanisms of acupuncture in patients with fibromyalgia (ClinicalTrials.gov identifier: NCT02583334). These lifestyle factors are recorded using a patient-reported questionnaire and should be able to provide more information regarding lifestyle. The third limitation was that detailed information on selected acupoints was not provided in the dataset. Acupoint selection was individualized according to the TCM diagnosis of patients and the experience of doctors, which is more like an effectiveness study. Most studies on the efficacy of acupuncture fix the acupoints to standardize their treatment protocol. The clinical trial of acupuncture in patients with fibromyalgia we conducted also fixed the acupoints as LI4, LI11, LR3, ST36, SP6, and GB34, which are commonly used acupoints for the treatment of patients with fibromyalgia.

Conclusions

Our present study confirms that acupuncture reduced the risk of CHD in patients with fibromyalgia in Taiwan. This noteworthy finding can provide some hints for further clinical and mechanistic studies.

Acknowledgements

This study was supported in part by China Medical University under the Aim for Top University Plan of the Ministry of Education, Taiwan. It was also supported by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019). This study was based in part on data derived from the NHIRD, provided by the NHIA, and the Ministry of Health and Welfare, and managed by the National Health Research Institutes. The interpretations and conclusions reported do not represent those of the NHIA, the Ministry of Health and Welfare, or the National Health Research Institutes. The funding agencies had no role in the study design, data collection and analyses, results interpretation, or publication of this study.

Funding

This study was supported in part by China Medical University under the Aim for Top University Plan of the Ministry of Education, Taiwan. It was also supported by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019).

Availability of supporting data

All data of this study are deposited in a properly managed public repository. We examined and analyzed datasets released from the Taiwan NHIRD (http://​nhird.​nhri.​org.​tw/​en/​index.​html), maintained and managed by National Health Research Institutes (http://​www.​nhri.​org.​tw/​), Taiwan. The use of the datasets is limited to research purposes only. Applicants must follow the Computer-Processed Personal Data Protection Law (http://​www.​winklerpartners.​com/​?​p=​987) and related regulations of the National Health Insurance Administration and the National Health Research Institutes, and the agreement must be signed by the applicant and his/her supervisor upon application submission. All applications are reviewed for approval of data release.

Authors’ contributions

MYW contributed to the conception and design of the study, participated in the interpretation of clinical data, and drafted the manuscript. MCH participated in the interpretation of clinical data and acupuncture treatment approaches. JHC performed the statistical analysis. MFS participated in the interpretation of clinical data. YCL participated in the interpretation of clinical data and acupuncture treatment approaches and also helped to finalize the manuscript. HRY conceived of the study, contributed to the interpretation of clinical data, and finalized the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
Not applicable in this section.
This study was approved by the research ethics committee of China Medical University and Hospital (CMUH104-REC2-115) and by the National Health Research Institute, the data holder of the NHI database. The need for patient consent was exempted on the basis of the total anonymity of all research data in this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20:25.CrossRefPubMed Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20:25.CrossRefPubMed
2.
Zurück zum Zitat Arnold LM, Gebke KB, Choy EH. Fibromyalgia: management strategies for primary care providers. Int J Clin Pract. 2016;70:99–112.CrossRefPubMed Arnold LM, Gebke KB, Choy EH. Fibromyalgia: management strategies for primary care providers. Int J Clin Pract. 2016;70:99–112.CrossRefPubMed
3.
Zurück zum Zitat Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600–10.CrossRef Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600–10.CrossRef
4.
5.
Zurück zum Zitat Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12:124–8.CrossRefPubMed Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12:124–8.CrossRefPubMed
6.
Zurück zum Zitat Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10, e0138024.CrossRefPubMedPubMedCentral Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10, e0138024.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Cho KI, Lee JH, Lee HG, Kim SM, Kim TI. Assessment of myocardial function in patients with fibromyalgia and the relationship to chronic emotional and physical stress. Korean Circ J. 2010;40:74–80.CrossRefPubMedPubMedCentral Cho KI, Lee JH, Lee HG, Kim SM, Kim TI. Assessment of myocardial function in patients with fibromyalgia and the relationship to chronic emotional and physical stress. Korean Circ J. 2010;40:74–80.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Su CH, Chen JH, Lan JL, Wang YC, Tseng CH, Hsu CY, et al. Increased risk of coronary heart disease in patients with primary fibromyalgia and those with concomitant comorbidity—a Taiwanese population-based cohort study. PLoS One. 2015;10, e0137137.CrossRefPubMedPubMedCentral Su CH, Chen JH, Lan JL, Wang YC, Tseng CH, Hsu CY, et al. Increased risk of coronary heart disease in patients with primary fibromyalgia and those with concomitant comorbidity—a Taiwanese population-based cohort study. PLoS One. 2015;10, e0137137.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Blumenthal DE, Malemud CJ. Recent strategies for drug development in fibromyalgia syndrome. Expert Rev Neurother. 2016;16:1407–11.CrossRefPubMed Blumenthal DE, Malemud CJ. Recent strategies for drug development in fibromyalgia syndrome. Expert Rev Neurother. 2016;16:1407–11.CrossRefPubMed
10.
Zurück zum Zitat Langhorst J, Klose P, Musial F, Irnich D, Häuser W. Efficacy of acupuncture in fibromyalgia syndrome—a systematic review with a meta-analysis of controlled clinical trials. Rheumatology (Oxford). 2010;49:778–88.CrossRef Langhorst J, Klose P, Musial F, Irnich D, Häuser W. Efficacy of acupuncture in fibromyalgia syndrome—a systematic review with a meta-analysis of controlled clinical trials. Rheumatology (Oxford). 2010;49:778–88.CrossRef
11.
Zurück zum Zitat Lin JG, Hsieh CL, Lin YW. Analgesic effect of electroacupuncture in a mouse fibromyalgia model: roles of TRPV1, TRPV4, and pERK. PLoS One. 2015;10, e0128037.CrossRefPubMedPubMedCentral Lin JG, Hsieh CL, Lin YW. Analgesic effect of electroacupuncture in a mouse fibromyalgia model: roles of TRPV1, TRPV4, and pERK. PLoS One. 2015;10, e0128037.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175:1527–9.CrossRefPubMed Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175:1527–9.CrossRefPubMed
13.
Zurück zum Zitat Chang CC, Lee YC, Lin CC, Chang CH, Chiu CD, Chou LW, et al. Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2016;186:311–21.CrossRefPubMed Chang CC, Lee YC, Lin CC, Chang CH, Chiu CD, Chou LW, et al. Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2016;186:311–21.CrossRefPubMed
14.
Zurück zum Zitat Yen HR, Lai WY, Muo CH, Sun MF. Characteristics of traditional Chinese medicine use in pediatric cancer patients: a nationwide, retrospective, Taiwanese-registry, population-based study. Integr Cancer Ther. doi:10.1177/1534735416659357. Yen HR, Lai WY, Muo CH, Sun MF. Characteristics of traditional Chinese medicine use in pediatric cancer patients: a nationwide, retrospective, Taiwanese-registry, population-based study. Integr Cancer Ther. doi:10.​1177/​1534735416659357​.
15.
Zurück zum Zitat Lien AS, Jiang YD, Mou CH, Sun MF, Gau BS, Yen HR. Integrative traditional Chinese medicine therapy reduces the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus. J Ethnopharmacol. 2016;191:324–30.CrossRefPubMed Lien AS, Jiang YD, Mou CH, Sun MF, Gau BS, Yen HR. Integrative traditional Chinese medicine therapy reduces the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus. J Ethnopharmacol. 2016;191:324–30.CrossRefPubMed
16.
Zurück zum Zitat Liao HH, Yeh CC, Lin CC, Chen BC, Yeh MH, Chang KM, et al. Prescription patterns of Chinese herbal products for patients with fractures in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015;173:11–9.CrossRefPubMed Liao HH, Yeh CC, Lin CC, Chen BC, Yeh MH, Chang KM, et al. Prescription patterns of Chinese herbal products for patients with fractures in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015;173:11–9.CrossRefPubMed
17.
Zurück zum Zitat Shih CC, Liao CC, Sun MF, Sun YC, Wen CP, Morisky DE, et al. Retrospective cohort study comparing stroke recurrence rate in ischemic stroke patients with and without acupuncture treatment. Medicine (Baltimore). 2015;94:e1572.CrossRef Shih CC, Liao CC, Sun MF, Sun YC, Wen CP, Morisky DE, et al. Retrospective cohort study comparing stroke recurrence rate in ischemic stroke patients with and without acupuncture treatment. Medicine (Baltimore). 2015;94:e1572.CrossRef
18.
Zurück zum Zitat LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am J Cardiol. 2013;111:1221–9.CrossRefPubMed LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am J Cardiol. 2013;111:1221–9.CrossRefPubMed
19.
Zurück zum Zitat Chen FP, Kung YY, Chen TJ, Hwang SJ. Demographics and patterns of acupuncture use in the Chinese population: the Taiwan experience. J Altern Complement Med. 2006;12:379–87.CrossRefPubMed Chen FP, Kung YY, Chen TJ, Hwang SJ. Demographics and patterns of acupuncture use in the Chinese population: the Taiwan experience. J Altern Complement Med. 2006;12:379–87.CrossRefPubMed
20.
Zurück zum Zitat Cramer H, Chung VC, Lauche R, Zhang Y, Zhang A, Langhorst J, et al. Characteristics of acupuncture users among internal medicine patients in Germany. Complement Ther Med. 2015;23:423–9.CrossRefPubMed Cramer H, Chung VC, Lauche R, Zhang Y, Zhang A, Langhorst J, et al. Characteristics of acupuncture users among internal medicine patients in Germany. Complement Ther Med. 2015;23:423–9.CrossRefPubMed
21.
Zurück zum Zitat Vas J, Santos-Rey K, Navarro-Pablo R, Modesto M, Aguilar I, Campos MÁ, et al. Acupuncture for fibromyalgia in primary care: a randomised controlled trial. Acupunct Med. 2016;34:257–66.CrossRefPubMed Vas J, Santos-Rey K, Navarro-Pablo R, Modesto M, Aguilar I, Campos MÁ, et al. Acupuncture for fibromyalgia in primary care: a randomised controlled trial. Acupunct Med. 2016;34:257–66.CrossRefPubMed
22.
Zurück zum Zitat Hadianfard MJ, Hosseinzadeh PM. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. Iran Red Crescent Med J. 2012;14:631–40.PubMedPubMedCentral Hadianfard MJ, Hosseinzadeh PM. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. Iran Red Crescent Med J. 2012;14:631–40.PubMedPubMedCentral
23.
Zurück zum Zitat Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc. 2006;81:749–57.CrossRefPubMed Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc. 2006;81:749–57.CrossRefPubMed
24.
Zurück zum Zitat Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39:448–53.CrossRefPubMed Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39:448–53.CrossRefPubMed
25.
Zurück zum Zitat Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73.CrossRefPubMed Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73.CrossRefPubMed
26.
Zurück zum Zitat Ho JM, Tricco AC, Perrier L, Chen M, Juurlink DN, Straus SE. Risk of heart failure and edema associated with the use of pregabalin: a systematic review. Syst Rev. 2013;2:25.CrossRefPubMedPubMedCentral Ho JM, Tricco AC, Perrier L, Chen M, Juurlink DN, Straus SE. Risk of heart failure and edema associated with the use of pregabalin: a systematic review. Syst Rev. 2013;2:25.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Lee SMK, Yoon KH, Park J, Kim HS, Woo JS, Lee SR, et al. Additional effects of back-shu electroacupuncture and moxibustion in cardioprotection of rat ischemia-reperfusion injury. Evid Based Complement Alternat Med. 2015;2015:625645.PubMed Lee SMK, Yoon KH, Park J, Kim HS, Woo JS, Lee SR, et al. Additional effects of back-shu electroacupuncture and moxibustion in cardioprotection of rat ischemia-reperfusion injury. Evid Based Complement Alternat Med. 2015;2015:625645.PubMed
28.
Zurück zum Zitat Ma L, Cui B, Shao Y, Ni B, Zhang W, Luo Y, et al. Electroacupuncture improves cardiac function and remodeling by inhibition of sympathoexcitation in chronic heart failure rats. Am J Physiol Heart Circ Physiol. 2014;306:H1464–71.CrossRefPubMed Ma L, Cui B, Shao Y, Ni B, Zhang W, Luo Y, et al. Electroacupuncture improves cardiac function and remodeling by inhibition of sympathoexcitation in chronic heart failure rats. Am J Physiol Heart Circ Physiol. 2014;306:H1464–71.CrossRefPubMed
29.
Zurück zum Zitat Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114–29.CrossRefPubMed Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114–29.CrossRefPubMed
30.
Zurück zum Zitat de Tommaso M, Delussi M, Ricci K, D’Angelo G. Abdominal acupuncture changes cortical responses to nociceptive stimuli in fibromyalgia patients. CNS Neurosci Ther. 2014;20:565–7.CrossRefPubMed de Tommaso M, Delussi M, Ricci K, D’Angelo G. Abdominal acupuncture changes cortical responses to nociceptive stimuli in fibromyalgia patients. CNS Neurosci Ther. 2014;20:565–7.CrossRefPubMed
31.
Zurück zum Zitat Lu KW, Hsieh CL, Yang J, Lin YW. Effects of electroacupuncture in a mouse model of fibromyalgia: role of N-methyl-d-aspartate receptors and related mechanisms. Acupunct Med. doi:10.1136/acupmed-2015-010986. Lu KW, Hsieh CL, Yang J, Lin YW. Effects of electroacupuncture in a mouse model of fibromyalgia: role of N-methyl-d-aspartate receptors and related mechanisms. Acupunct Med. doi:10.​1136/​acupmed-2015-010986.
32.
Zurück zum Zitat McGee MA, Abdel-Rahman AA. N-methyl-d-aspartate receptor signaling and function in cardiovascular tissues. J Cardiovasc Pharmacol. 2016;68:97–105.CrossRefPubMed McGee MA, Abdel-Rahman AA. N-methyl-d-aspartate receptor signaling and function in cardiovascular tissues. J Cardiovasc Pharmacol. 2016;68:97–105.CrossRefPubMed
33.
Zurück zum Zitat Shi S, Liu T, Wang D, Zhang Y, Liang J, Yang B, et al. Activation of N-methyl-d-aspartate receptors reduces heart rate variability and facilitates atrial fibrillation in rats. Europace. doi:10.1093/europace/euw086. Shi S, Liu T, Wang D, Zhang Y, Liang J, Yang B, et al. Activation of N-methyl-d-aspartate receptors reduces heart rate variability and facilitates atrial fibrillation in rats. Europace. doi:10.​1093/​europace/​euw086.
34.
Zurück zum Zitat Seo BK, Sung WS, Park YC, Baek YH. The electroacupuncture-induced analgesic effect mediated by 5-HT1, 5-HT3 receptor and muscarinic cholinergic receptors in rat model of collagenase-induced osteoarthritis. BMC Complement Altern Med. 2016;16:212.CrossRefPubMedPubMedCentral Seo BK, Sung WS, Park YC, Baek YH. The electroacupuncture-induced analgesic effect mediated by 5-HT1, 5-HT3 receptor and muscarinic cholinergic receptors in rat model of collagenase-induced osteoarthritis. BMC Complement Altern Med. 2016;16:212.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Seidel MF, Weinreich GF, Stratz T, Müller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int. 2007;27:1025–30.CrossRefPubMed Seidel MF, Weinreich GF, Stratz T, Müller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int. 2007;27:1025–30.CrossRefPubMed
36.
Zurück zum Zitat Xiong S, Wang P, Ma L, Gao P, Gong L, Li L, et al. Ameliorating endothelial mitochondrial dysfunction restores coronary function via transient receptor potential vanilloid 1-mediated protein kinase A/uncoupling protein 2 pathway. Hypertension. 2016;67:451–60.PubMed Xiong S, Wang P, Ma L, Gao P, Gong L, Li L, et al. Ameliorating endothelial mitochondrial dysfunction restores coronary function via transient receptor potential vanilloid 1-mediated protein kinase A/uncoupling protein 2 pathway. Hypertension. 2016;67:451–60.PubMed
37.
Zurück zum Zitat Shergis JL, Ni X, Jackson ML, Zhang AL, Guo X, Li Y, et al. A systematic review of acupuncture for sleep quality in people with insomnia. Complement Ther Med. 2016;26:11–20.CrossRefPubMed Shergis JL, Ni X, Jackson ML, Zhang AL, Guo X, Li Y, et al. A systematic review of acupuncture for sleep quality in people with insomnia. Complement Ther Med. 2016;26:11–20.CrossRefPubMed
39.
41.
Zurück zum Zitat Le JJ, Yi T, Qi L, Li J, Shao L, Dong JC. Electroacupuncture regulate hypothalamic-pituitary-adrenal axis and enhance hippocampal serotonin system in a rat model of depression. Neurosci Lett. 2016;615:66–71.CrossRefPubMed Le JJ, Yi T, Qi L, Li J, Shao L, Dong JC. Electroacupuncture regulate hypothalamic-pituitary-adrenal axis and enhance hippocampal serotonin system in a rat model of depression. Neurosci Lett. 2016;615:66–71.CrossRefPubMed
42.
Zurück zum Zitat Lu J, Shao RH, Hu L, Tu Y, Guo JY. Potential antiinflammatory effects of acupuncture in a chronic stress model of depression in rats. Neurosci Lett. 2016;618:31–8.CrossRefPubMed Lu J, Shao RH, Hu L, Tu Y, Guo JY. Potential antiinflammatory effects of acupuncture in a chronic stress model of depression in rats. Neurosci Lett. 2016;618:31–8.CrossRefPubMed
43.
Zurück zum Zitat Torres-Rosas R, Yehia G, Peña G, Mishra P, del Rocio Thompson-Bonilla M, Moreno-Eutimio MA, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med. 2014;20:291–5.CrossRefPubMedPubMedCentral Torres-Rosas R, Yehia G, Peña G, Mishra P, del Rocio Thompson-Bonilla M, Moreno-Eutimio MA, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med. 2014;20:291–5.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Zhao C, Bao C, Li J, Zhu Y, Wang S, Yang L, et al. Moxibustion and acupuncture ameliorate Crohn’s disease by regulating the balance between Th17 and Treg cells in the intestinal mucosa. Evid Based Complement Alternat Med. 2015;2015:938054.PubMedPubMedCentral Zhao C, Bao C, Li J, Zhu Y, Wang S, Yang L, et al. Moxibustion and acupuncture ameliorate Crohn’s disease by regulating the balance between Th17 and Treg cells in the intestinal mucosa. Evid Based Complement Alternat Med. 2015;2015:938054.PubMedPubMedCentral
45.
Zurück zum Zitat Wang Q, Liang D, Wang F, Li W, Han Y, Zhang W, et al. Efficacy of electroacupuncture pretreatment for myocardial injury in patients undergoing percutaneous coronary intervention: a randomized clinical trial with a 2-year follow-up. Int J Cardiol. 2015;194:28–35.CrossRefPubMed Wang Q, Liang D, Wang F, Li W, Han Y, Zhang W, et al. Efficacy of electroacupuncture pretreatment for myocardial injury in patients undergoing percutaneous coronary intervention: a randomized clinical trial with a 2-year follow-up. Int J Cardiol. 2015;194:28–35.CrossRefPubMed
Metadaten
Titel
Acupuncture decreased the risk of coronary heart disease in patients with fibromyalgia in Taiwan: a nationwide matched cohort study
verfasst von
Mei-Yao Wu
Ming-Cheng Huang
Jen-Huai Chiang
Mao-Feng Sun
Yu-Chen Lee
Hung-Rong Yen
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 1/2017
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1239-7

Weitere Artikel der Ausgabe 1/2017

Arthritis Research & Therapy 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.